Compro (Prochlorperazine Rectal) - Summary

COMPRO SUMMARY

COMPRO^®
PROCHLORPERAZINE SUPPOSITORIES USP, 25mg

Prochlorperazine is a clear, pale yellow, viscous liquid. It is sensitive to light, very slightly soluble in water, freely soluble in alcohol, in chloroform, and in ether. Each suppository, for rectal administration, contains 25 mg of prochlorperazine; with glycerin, glyceryl monopalmitate, glyceryl monostearate, hydrogenated coconut oil fatty acids and hydrogenated palm kernel oil fatty acids.

Prochlorperazine 25mg suppositories are indicated in the control of severe nausea and vomiting in adults.

See all Compro indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Compro (Prochlorperazine Rectal)

Engineered Biomaterial Could Eliminate The Body's Negative Reaction To Medical Implants
Source: Immune System / Vaccines News From Medical News Today [2013.05.16]
It's a familiar scenario - a patient receives a medical implant and days later, the body attacks the artificial valve or device, causing complications to an already compromised system. Expensive, state-of-the-art medical devices and surgeries often are thwarted by the body's natural response to attack something in the tissue that appears foreign...

ASCO: More Radiation No Good in NSCLC
Source: MedPage Today Oncology/Hematology [2013.05.15]
CHICAGO (MedPage Today) -- Boosting the dose of radiation therapy in stage III non-small cell lung cancer actually compromises outcomes and cuts survival, a randomized trial showed.

The Search For Therapeutic Synergy In Primary Effusion Lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2013.05.03]
Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with HIV and the elderly. Because current treatment options are not effective, there is a great need for new PEL therapies...

Influenza Testing And Management Streamlined By Improved Molecular Tools
Source: Flu / Cold / SARS News From Medical News Today [2013.04.19]
Over 40,000 people die each year in the United States from influenza-related diseases. In patients whose immune systems are compromised, antiviral therapy may be life-saving, but it needs to be initiated quickly. It is therefore crucial to diagnose and type the influenza rapidly...

Nausea and Vomiting
Source: MedicineNet Anthrax Specialty [2012.04.24]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 8:21:00 AM
Last Editorial Review: 4/24/2012 12:00:00 AM

more news >>

Published Studies Related to Compro (Prochlorperazine Rectal)

Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache. [2011.04.01]
The indomethacin/prochlorperazine/caffeine fixed combination (Difmetre(R)) combines the NSAID indomethacin with the phenothiazine antiemetic prochlorperazine and caffeine. It is currently available as two oral (effervescent tablet and coated tablet) and two rectal (suppository and low-dose suppository) formulations...

more studies >>

Clinical Trials Related to Compro (Prochlorperazine Rectal)

Staccato® Prochlorperazine for Inhalation [Completed]

Staccato Prochlorperazine in Patients With Migraine Headache [Completed]

Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department [Completed]
ED patients with acute migraine will be randomized to either prochlorperazine and Bendaryl OR imitrex. VAS for pain will be monitored, along with side effects. Primary outcome measure is improvement in pain scales between the groups.

Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department [Recruiting]
This study will compare the effect of prochlorperazine and ondansetron for the treatment of nausea and vomiting in the emergency department.

Staccato® Prochlorperazine for Inhalation in Migraine [Completed]
Staccato Prochlorperazine is being developed to treat patients suffering from acute migraine headaches. In October 2005, we completed a 75 patient, multi-center, double-blind placebo-controlled Phase 2A clinical trial in patients suffering from moderate to severe acute migraine headaches. This Phase 2B clinical trial of Staccato Prochlorperazine has been initiated to assess the efficacy and safety in outpatients with migraine headache with or without aura.

more trials >>